首頁 > 市場調查報告書 > 製藥

醫藥品法規環境

市場調查報告書

商品編碼

1982866

全球藥品安全監測市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Pharmacovigilance Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 228 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計藥品安全監測市場將從 2025 年的 89.4 億美元成長到 2034 年的 164.4 億美元，2026 年至 2034 年的複合年成長率為 7.01%。

隨著製藥業日益重視藥物安全和監測，全球藥物安全監測市場正迅速擴張。藥物安全監測是指藥物相關不利事件進行檢測、評估及預防。這在確保患者安全和維持藥物整個生命週期的合規性方面發揮著至關重要的作用。

多種因素正在推動藥物安全監測市場的成長。臨床試驗和新核准藥物數量的增加，推動了上市後監測和安全監控的需求。監管機構也在實施嚴格的安全指南，要求製藥公司密切監測不利事件。此外，現代藥物療法的日益複雜化，也使得先進的藥物安全監測系統變得愈發重要。

隨著醫療保健系統持續將病人安全放在首位，藥物安全監測市場前景十分光明。數據分析、人工智慧和數位健康技術的進步正在提高安全監測流程的效率。隨著全球醫藥創新不斷拓展，藥物安全監測仍將是藥物研發和醫療保健監管中不可或缺的重要組成部分。

區域分析
北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 其他亞太國家
拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家

第11章競爭格局

最新趨勢
公司分類
供應鏈和銷售管道合作夥伴（根據現有資訊）
市場佔有率和市場定位分析（基於現有資訊）
供應商情況（基於現有資訊）
策略規劃

第12章：公司簡介

主要公司的市佔率分析
公司簡介
- Accenture
- IQVIA Inc
- Cognizant
- Clinquest Group BV（Linical Americas）
- IBM
- Laboratory Corporation Of America Holdings
- ArisGlobal
- Capgemini
- ITClinical
- ICON Plc
- TAKE Solutions Limited
- Parexel International（MA）Corporation
- Wipro
- United BioSource LLC
- BioClinica Inc.（Clario）
- ClinChoice（Formerly FMD K&L）

簡介目錄

Product Code: VMR11212767

The Pharmacovigilance Market size is expected to reach USD 16.44 Billion in 2034 from USD 8.94 Billion (2025) growing at a CAGR of 7.01% during 2026-2034.

The global pharmacovigilance market is expanding rapidly as the pharmaceutical industry places greater emphasis on drug safety and monitoring. Pharmacovigilance involves the detection, assessment, and prevention of adverse effects related to pharmaceutical products. It plays a critical role in ensuring patient safety and maintaining regulatory compliance throughout the lifecycle of a drug.

Several factors are driving the growth of the pharmacovigilance market. The increasing number of clinical trials and newly approved drugs is creating a greater need for post-marketing surveillance and safety monitoring. Regulatory authorities are also implementing strict safety guidelines that require pharmaceutical companies to monitor adverse drug reactions carefully. Additionally, the growing complexity of modern drug therapies is increasing the importance of advanced pharmacovigilance systems.

The future outlook for the pharmacovigilance market is highly promising as healthcare systems continue to prioritize patient safety. Advances in data analytics, artificial intelligence, and digital health technologies are improving the efficiency of safety monitoring processes. As pharmaceutical innovation continues to expand globally, pharmacovigilance will remain a crucial component of drug development and healthcare regulation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Life Cycle

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

By Service Provider

In-house
Contract Outsourcing

By Type

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

By End Use

Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others

By Therapeutic Area

Oncology
Neurology
Cardiology
Respiratory Systems
Others

By Process Flow

Case Data Management
Medical Reviewing & Reporting
Signal Detection
Risk Management System

COMPANIES PROFILED

Accenture, IQVIA Inc, Cognizant, Clinquest Group BV Linical Americas, IBM, Laboratory Corporation of America Holdings, ArisGlobal, Capgemini, ITClinical, ICON plc, TAKE Solutions Limited, Parexel International MA Corporation, Wipro, United BioSource LLC, BioClinica Inc Clario, ClinChoice formerly FMD KL
We can customise the report as per your requirements.

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACOVIGILANCE MARKET: BY PRODUCT LIFE CYCLE 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product Life Cycle
4.2. Pre-clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACOVIGILANCE MARKET: BY SERVICE PROVIDER 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Service Provider
5.2. In-house Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Contract Outsourcing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACOVIGILANCE MARKET: BY TYPE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Type
6.2. Spontaneous Reporting Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Intensified ADR Reporting Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Targeted Spontaneous Reporting Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Cohort Event Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.6. EHR Mining Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PHARMACOVIGILANCE MARKET: BY END USE 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast End Use
7.2. Pharmaceuticals Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Medical Device Manufacturers Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PHARMACOVIGILANCE MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

8.1. Market Analysis, Insights and Forecast Therapeutic Area
8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.4. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.5. Respiratory Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PHARMACOVIGILANCE MARKET: BY PROCESS FLOW 2022-2034 (USD MN)

9.1. Market Analysis, Insights and Forecast Process Flow
9.2. Case Data Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.3. Medical Reviewing & Reporting Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.4. Signal Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
9.5. Risk Management System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL PHARMACOVIGILANCE MARKET: BY REGION 2022-2034(USD MN)

10.1. Regional Outlook
10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.2.1 By Product Life Cycle
- 10.2.2 By Service Provider
- 10.2.3 By Type
- 10.2.4 By End Use
- 10.2.5 By Therapeutic Area
- 10.2.6 By Process Flow
- 10.2.7 United States
- 10.2.8 Canada
- 10.2.9 Mexico
10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.3.1 By Product Life Cycle
- 10.3.2 By Service Provider
- 10.3.3 By Type
- 10.3.4 By End Use
- 10.3.5 By Therapeutic Area
- 10.3.6 By Process Flow
- 10.3.7 United Kingdom
- 10.3.8 France
- 10.3.9 Germany
- 10.3.10 Italy
- 10.3.11 Russia
- 10.3.12 Rest Of Europe
10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.4.1 By Product Life Cycle
- 10.4.2 By Service Provider
- 10.4.3 By Type
- 10.4.4 By End Use
- 10.4.5 By Therapeutic Area
- 10.4.6 By Process Flow
- 10.4.7 India
- 10.4.8 Japan
- 10.4.9 South Korea
- 10.4.10 Australia
- 10.4.11 South East Asia
- 10.4.12 Rest Of Asia Pacific
10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.5.1 By Product Life Cycle
- 10.5.2 By Service Provider
- 10.5.3 By Type
- 10.5.4 By End Use
- 10.5.5 By Therapeutic Area
- 10.5.6 By Process Flow
- 10.5.7 Brazil
- 10.5.8 Argentina
- 10.5.9 Peru
- 10.5.10 Chile
- 10.5.11 South East Asia
- 10.5.12 Rest of Latin America
10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 10.6.1 By Product Life Cycle
- 10.6.2 By Service Provider
- 10.6.3 By Type
- 10.6.4 By End Use
- 10.6.5 By Therapeutic Area
- 10.6.6 By Process Flow
- 10.6.7 Saudi Arabia
- 10.6.8 UAE
- 10.6.9 Israel
- 10.6.10 South Africa
- 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

11.1. Recent Developments
11.2. Company Categorization
11.3. Supply Chain & Channel Partners (based on availability)
11.4. Market Share & Positioning Analysis (based on availability)
11.5. Vendor Landscape (based on availability)
11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL PHARMACOVIGILANCE INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Company Profiles
- 12.2.1 Accenture
- 12.2.2 IQVIA Inc
- 12.2.3 Cognizant
- 12.2.4 Clinquest Group B.V. (Linical Americas)
- 12.2.5 IBM
- 12.2.6 Laboratory Corporation Of America Holdings
- 12.2.7 ArisGlobal
- 12.2.8 Capgemini
- 12.2.9 ITClinical
- 12.2.10 ICON Plc
- 12.2.11 TAKE Solutions Limited
- 12.2.12 Parexel International (MA) Corporation
- 12.2.13 Wipro
- 12.2.14 United BioSource LLC
- 12.2.15 BioClinica Inc. (Clario)
- 12.2.16 ClinChoice (Formerly FMD K&L)